FDA Calls For Pre-Market CV Safety Trials For Some Constipation Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Serotonin receptor 4 agonists for use in constipation have been in limbo due to potential for CV risk; FDA is seeking recommendations about safety studies for the class from an advisory committee.
You may also be interested in...
The New Zelnorm-al (Part 2): More Thoughts On The Revival Of The 5HT4 Class
Looming return of Zelnorm to US market is milestone event for current regulatory climate. But FDA’s hands-on work to resurrect a different 5HT4 agonist, prucalopride, probably says more about what is truly different about the agency today.
VC-backed GI Start-Ups See Opportunity In IBS
Private companies developing drugs for gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome hope to take advantage of a resurging interest in the space after linaclotide developer Ironwood Pharmaceuticals has shown its novel, locally acting guanylate cyclise type-C agonist is efficacious in four Phase III trials. We profile four such hopefuls in this issue: Altheus Therapeutics, AltheRx Pharmaceuticals, Aldrex and Second Genome.
GI Drugs Cmte. To Weigh Retreatment Study Design For Salix's Xifaxan In Irritable Bowel
On Nov. 16, FDA's outside advisors will discuss the design of clinical trials to evaluate the safety, efficacy and durability of response with repeat treatment cycles of rifaximin for diarrhea-predominant IBS.